Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. - Wikidata - awgldk - TriplyDB

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

http://www.wikidata.org/entity/Q51926211

about

Vaccines: from empirical development to rational design Design and pre-clinical evaluation of a universal HIV-1 vaccine Immunoinformatics comes of age Viral evolution and escape during acute HIV-1 infection HIV-1 prophylactic vaccines: state of the art HIV-Host Interactions: Implications for Vaccine Design Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?Mechanisms of HIV protein degradation into epitopes: implications for vaccine design A global approach to HIV-1 vaccine development Sang Froid in a time of trouble: is a vaccine against HIV possible?Different Vaccine Vectors Delivering the Same Antigen Elicit CD8+ T Cell Responses with Distinct Clonotype and Epitope Specificity New concepts in HIV-1 vaccine development Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design The Number and Complexity of Pure and Recombinant HIV-1 Strains Observed within Incident Infections during the HIV and Malaria Cohort Study Conducted in Kericho, Kenya, from 2003 to 2006 Measurements of immune responses for establishing correlates of vaccine protection against HIV Increased breadth and depth of cytotoxic T lymphocytes responses against HIV-1-B Nef by inclusion of epitope variant sequences Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets Current views on the potential for development of a HIV vaccine.DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS.Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications.Vaccine design for CD8 T lymphocyte responses Human immunodeficiency virus vaccine trials Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection.A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.A statistical framework for modeling HLA-dependent T cell response data.Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques.HIV-1 group M conserved elements vaccine.Hotspot Hunter: a computational system for large-scale screening and selection of candidate immunological hotspots in pathogen proteomes.Molecular evolution of human immunodeficiency virus type 1 upon transmission between human leukocyte antigen disparate donor-recipient pairs.A mathematical framework for the selection of an optimal set of peptides for epitope-based vaccines.Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy.High throughput T epitope mapping and vaccine development HIV-1 vaccine development after STEP.Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing.Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys.

P2860

Q21089599-6E25A95C-5761-4F1B-BCDA-2082EC67AC61 Q21092234-30689D5F-C8FE-46D5-B916-D8A64DF9A180 Q21145682-601680DF-06D6-41A4-8DD3-F60B2EF27A56 Q24600713-2D704036-AE31-4B5A-8DB3-ED30FD44B511 Q26740042-717A0CFE-C93F-4A7C-8193-684D655602A5 Q26765966-B2CFC1F1-FEED-4A56-9E95-164CFB217B8D Q26865388-0F5033AC-29A5-4E8D-973A-C571EFEF0080 Q26866505-543BB347-AEB3-4F73-B07A-602AEBF37C23 Q27024614-110172DD-789B-4AB1-9DDC-F0DDDA9F279F Q27487961-9F33B638-DF70-46AF-93B7-739A23DC7707 Q27646554-8DA5B29E-00AE-49F9-A8B8-4843E22F2A25 Q28067027-513A4708-E940-4999-A798-013748004D89 Q28472597-85516940-7673-40DC-A326-EE854BFC1CC2 Q28602408-D58A61CD-3A6D-4519-B7BE-F9DF76133CCF Q28608652-302BD050-270D-43AF-BCC9-B9C39829B5BF Q28728189-90DE82F4-D06C-4FA9-84DA-9DBED314079A Q28741616-A4C7BD36-37BB-44ED-8D85-08A363FA6699 Q28743767-BF0CE677-152F-425B-A29D-DB41ECE5F364 Q28822525-FB1AB6EC-AF06-4369-9EB4-B67B8DF0F864 Q30207890-C708566D-7C96-44E2-AFEE-0F56448A5E24 Q30366017-8F77235A-D036-4757-AB88-B8C08A061CAE Q30397595-5AE39BB8-6EC2-4095-940F-29FDCCFD3D0F Q30408029-E4896484-3223-43AA-AEA0-840BF53C20A3 Q30410411-6D62059E-F06B-4FDB-ACA0-AF8471FCB29C Q30411492-81054BD7-B310-44BC-8C2D-1D41A6E2C57A Q30424366-3F42AF7F-32D4-4D14-8FA5-F36470BC80E3 Q30469621-B5C039DA-5F68-4ECD-8576-068E11EC47A2 Q30934059-DAE7FFA7-ABEB-4D6D-BCB9-1696A0EA1524 Q31133137-3793A64C-FDA2-49DE-9037-AB62183F1BF8 Q31148797-AACE4CCB-EC49-4FBD-AFA4-76FA12E40839 Q33308246-5722C9CF-380C-4F77-8741-A0AC2C494D09 Q33322206-6C875605-B619-42AF-968C-7F41316916C8 Q33344499-34E10F9B-BD76-4665-96E9-B1A226E5C2DD Q33396199-22C768A8-3EB6-4707-8AD5-3A094CFB4E86 Q33578049-FAF5AF28-9A1E-4650-B67A-2BA1D4484940 Q33611645-E208F632-A527-4312-B042-4594901FF9BD Q33628719-B6A2A5D6-F122-4EF9-ACD1-940A56673361 Q33642318-92164C5B-D3EA-4C3C-9C20-9C97D590D8A4 Q33680395-600A9319-B21A-4D5C-B9DC-A7448FD1AE0D Q33712291-F4C7208D-6FA8-4697-B48C-26ACC870A9E4

P2860

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

http://www.wikidata.org/entity/Q51926211

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Polyvalent vaccines for optima ...... opes in global HIV-1 variants.

@en

Polyvalent vaccines for optima ...... opes in global HIV-1 variants.

@nl

type

label

Polyvalent vaccines for optima ...... opes in global HIV-1 variants.

@en

Polyvalent vaccines for optima ...... opes in global HIV-1 variants.

@nl

prefLabel

Polyvalent vaccines for optima ...... opes in global HIV-1 variants.

@en

Polyvalent vaccines for optima ...... opes in global HIV-1 variants.

@nl

P1433

Q51926211-A91E9405-8877-4C09-9F3F-3A2607AD0410

P1476

Q51926211-1A11CDFF-3884-4258-A98A-62FF343B3B08

P2093

Q51926211-32D7D53E-E6EB-47C9-9505-46F6FE3461E9

Q51926211-4F528EDF-043A-498D-A77F-06EF68F48824

Q51926211-61E3C0D8-5F73-48E6-BB32-C1059205ABFB

Q51926211-69A5438C-BF64-400A-A20F-962D196D8A29

Q51926211-D990A214-488E-4EA0-8F66-D17FDDD81D57

Q51926211-F7BD829A-E6FF-4209-B0B7-AB2119586867

P2860

Q51926211-2864DCE4-0A3B-4E60-993D-F5713B0F5796

Q51926211-2C3B0AD7-6CD4-4505-8E87-603EA90F2545

Q51926211-331F8824-4119-4468-908E-10618531FB58

Q51926211-3574AE9C-37B2-4F85-8EDD-0F3D55FEFF9A

Q51926211-3FF97BC4-E3F2-4E2F-9AB5-4A6B7391FF9B

Q51926211-45ECE845-DB26-4161-AFFF-5EB63F792B95

Q51926211-4B2CC48B-2AD3-4CB1-8E23-1C5CE47BEE85

Q51926211-4B91A662-465F-4F79-9505-DBB52E80FD37

Q51926211-5994CB8E-5CB3-433C-8F24-4D3D38E5BA73

Q51926211-5AB6A73F-F3AC-409F-BC15-2057CEC91A19

P2888

Q51926211-1ECE9D37-99C5-4C8A-9ACD-A0FC6BA6E8B4

P304

Q51926211-C2E2E2E9-59F0-47D5-83D1-EF1FED2A4788

P31

Q51926211-758D899F-9B51-42DB-B4B1-2CF0EFDF9E98

P356

Q51926211-1CBF395F-7D2B-45CA-9C10-F671FB12DD79

P407

Q51926211-05618B29-4812-4E44-99CD-2B2263812753

P433

Q51926211-D4160348-7FC3-4F26-AC7B-E0B497D4AFBF

P478

Q51926211-2ABF0DEE-1577-4EEE-9AD7-B8E043DCCCB1

P50

Q51926211-5BD1599E-B93E-44EF-AF0A-D620CE0F7EEA

Q51926211-617C096D-EA78-4AFC-9D3B-A53C25C2F32C

Q51926211-92798635-2AB1-42C5-B1F9-BA0431D7FDCC

Q51926211-99438F33-75F4-42C3-BB34-4F78CD217C58

Q51926211-A2D358AB-77EA-4F55-9539-4EF13A3B9DC4

Q51926211-D2186BEE-5E51-44BA-AFAA-878F476627F5

P577

Q51926211-2536E98C-F463-4326-BF12-5B28627EC7EB

P5875

Q51926211-2E128B26-51E2-43E6-BD08-B83F6EDDE90F

P698

Q51926211-A17DD2A8-E827-4021-89BB-D777B1619B05

P356

P1433

Nature Medicine

P1476

Polyvalent vaccines for optima ...... opes in global HIV-1 variants.

@en

P2093

Carla Kuiken

http://www.w3.org/2001/XMLSchema#string

James Theiler

http://www.w3.org/2001/XMLSchema#string

Karina Yusim

http://www.w3.org/2001/XMLSchema#string

Norman L Letvin

http://www.w3.org/2001/XMLSchema#string

Robert Funkhouser

http://www.w3.org/2001/XMLSchema#string

Simon Perkins

http://www.w3.org/2001/XMLSchema#string

P2860

HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway

Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

Evolutionary and immunological implications of contemporary HIV-1 variation.

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.

De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection

Diversity considerations in HIV-1 vaccine selection.

HIV vaccine strategies.

Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen

Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences.

P2888

P304

100-106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM1461

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Bruce D. Walker

Beatrice H. Hahn

Tanmoy Bhattacharya

P577

2006-12-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6613538

http://www.w3.org/2001/XMLSchema#string

P698

17187074

http://www.w3.org/2001/XMLSchema#string